Clinical Significance of SEC11A Expression in Patients With Locally Advanced Gastric Cancer

Anticancer Res. 2022 Dec;42(12):5885-5890. doi: 10.21873/anticanres.16097.

Abstract

Background/aim: SEC11A gene encodes the SPC18 protein, which has been implicated in tumour progression by inducing the secretion of various growth factors. We investigated the clinical significance of SEC11A expression in gastric cancer (GC) tissues in patients with locally advanced gastric cancer (LAGC) after curative resection.

Patients and methods: We estimated SEC11A expression in cancer tissues from 253 pStage II/III GC patients who underwent curative resection using quantitative polymerase chain reaction (PCR) and investigated the relationship of SEC11A expression with clinicopathological factors and survival.

Results: SEC11A expression was significantly related to serosal invasion, lymph node metastasis, lymphatic invasion, and pathological stage. The high-SEC11A expression group had a significantly lower survival rate than the low group (5-year survival 52.3% vs. 75.9%; p<0.005). Furthermore, in multivariate analysis, high-SEC11A expression was an independent factor of poor survival (hazard ratio, 2.010; 95% confidence interval=1.303-3.100; p=0.002).

Conclusion: SEC11A expression in cancer tissue may be a useful prognostic marker in patients with LAGC after curative resection.

Keywords: Gastric cancer; SEC11A; SPC18.

MeSH terms

  • Humans
  • Lymphatic Metastasis
  • Multivariate Analysis
  • Neoplasms, Second Primary*
  • Peptide Hydrolases
  • Stomach Neoplasms* / genetics
  • Stomach Neoplasms* / surgery

Substances

  • SEC11A protein, human
  • Peptide Hydrolases